Longyu Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Longyu Xu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Baosheng Li
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
7 shared publications - Bingjie Fan
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
7 shared publications - Chengrui Fu
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
7 shared publications - Chengxin Liu
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
7 shared publications - Dan Han
Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong, People’s Republic of China
7 shared publications - Hongfu Sun
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
7 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
FIgure S4 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 4. Comparison of immune dynamics between responders and non-responders.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIgure S4 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 4. Comparison of immune dynamics between responders and non-responders.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 1. Subgroup analysis of progression-free survival (PFS).
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 1. Subgroup analysis of progression-free survival (PFS).
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
FIgure S2 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 2. Sensitivity analysis of survival outcomes.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIgure S2 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 2. Sensitivity analysis of survival outcomes.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
FIgure S3 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 3. Longitudinal dynamics of peripheral blood lymphocytes.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIgure S3 from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Supplementary Figure 3. Longitudinal dynamics of peripheral blood lymphocytes.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.
- Open Access
- 30 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (6) , 1035-1044
Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.
- 30 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (6) , 1035-1044
Open AccessInduction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (3) , 899-908
D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have emerged as a new choice for advanced and metastatic gastric cancer (GC) patients. Due to the lack of unified and effective predictive biomarkers, there is an urgent need to find accurate biomarkers. The aim of our study was to explore the prognostic value of the pretreatment D-dimer levels on the effect of immunotherapy combined with chemotherapy in advanced and metastatic GC patients. Methods: We retrospectively reviewed 40 advanced and metastatic GC patients receiving programmed death 1/programmed death ligand-1 (PD-1/PD-L1) inhibitors. The optimal D-dimer cut-off value was calculated based on the Youden index for overall survival (OS). The efficacy and prognostic outcomes of ICIs combined with chemotherapy in patients with advanced or metastatic GC were assessed across subgroups stratified by pretreatment D-dimer levels. Univariate and multivariate regression analyses were performed to evaluate the potential prognostic factors for progression-free survival (PFS) and OS. Results: The optimal cut-off value of D-dimer was 0.965 µg/mL, with a sensitivity and specificity of 0.857 and 0.789, respectively, based on the receiver operating characteristic (ROC) curve and Youden index. The low D-dimer group exhibited higher disease control rate (DCR) compared to the high D-dimer group (72.2% vs. 22.7%, P=0.002). The median PFS in the low D-dimer group was 13.6 months, in comparison with 4.4 months in the high D-dimer group (PConclusions: Pretreatment D-dimer level may be an independent predictive biomarker for efficacy and prognosis in advanced and metastatic GC patients receiving first-line immunotherapy combined with chemotherapy.
- 1 June 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (3) , 899-908
Open AccessD-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have emerged as a new choice for advanced and metastatic gastric cancer (GC) patients. Due to the lack of unified and effective predictive biomarkers, there is an urgent need to find accurate biomarkers. The aim of our study was to explore the prognostic value of the pretreatment D-dimer levels on the effect of immunotherapy combined with chemotherapy in advanced and metastatic GC patients. Methods: We retrospectively reviewed 40 advanced and metastatic GC patients receiving programmed death 1/programmed death ligand-1 (PD-1/PD-L1) inhibitors. The optimal D-dimer cut-off value was calculated based on the Youden index for overall survival (OS). The efficacy and prognostic outcomes of ICIs combined with chemotherapy in patients with advanced or metastatic GC were assessed across subgroups stratified by pretreatment D-dimer levels. Univariate and multivariate regression analyses were performed to evaluate the potential prognostic factors for progression-free survival (PFS) and OS. Results: The optimal cut-off value of D-dimer was 0.965 µg/mL, with a sensitivity and specificity of 0.857 and 0.789, respectively, based on the receiver operating characteristic (ROC) curve and Youden index. The low D-dimer group exhibited higher disease control rate (DCR) compared to the high D-dimer group (72.2% vs. 22.7%, P=0.002). The median PFS in the low D-dimer group was 13.6 months, in comparison with 4.4 months in the high D-dimer group (PConclusions: Pretreatment D-dimer level may be an independent predictive biomarker for efficacy and prognosis in advanced and metastatic GC patients receiving first-line immunotherapy combined with chemotherapy.